Erythromycin is a macrolide antibiotic with a spectrum similar to penicillin and is used mainly in the treatment of infections caused by gram-positive organisms. Since its discovery in 1952, erythromycin has achieved wide-spread clinical use. Susceptibility of erythromycin base to inactivation by acid results in decreased availability following exposure to acidic gastric fluids. Formulation of acid resistant dosage forms and the preparation of acid stable chemical derivatives have been attempted to improve absorption and subsequent clinical efficacy . Two of the most commonly used erythromycin derivatives are the stearic acid salt (erythromycin stearate) and the lauryl sulphate salt of the propionyl ester (erythromycin estolate). Although it has been known for many years that erythromycin is susceptible to acid degradation, very few reports on the stability of erythromycin in aqueous solutions appear in the literature. In this study, a high-performance liquid chromatographic system using electrochemical detection was employed for a kinetic study of erythromycin degradation. The effect of varying acid pH on the degradation rate of both erythromycin base and erythromycin stearate, and the effect on the hydrolysis rate of erythromycin estolate is presented. In addition, the effect of temperature on erythromycin degradation was also investigated. Until recently, the majority of pharmacokinetic and bioavailability studies have utilized relatively non-specific microbiological assay procedures. However, in this study a solid phase extraction, followed by the use of a high-performance liquid chromatographic system using electrochemical coulometric detection was employed for the determination of erythromycin in biological fluids. Human volunteers each received enteric coated erythromycin base pellets in capsule dosage form and also film coated erythromycin stearate tablets on separate occasions. Results from the clinical trials revealed the enteric coated erythromycin base pellets had a greater bioavailability than the film coated erythromycin stearate tablets. Computer fitting of data revealed no intra-volunteer variability in elimination rate constants, suggesting differences in serum levels following administration of both dosage forms are due to variation in absorption. Results from the clinical trials were also compared with those obtained from a further trial, during which the same volunteers received erythromycin estolate

Nitrile biocatalysts are of use in the chemical and pharmaceutical industries for the synthesis of carboxyamides and carboxylic acids. In particular, the application of biocatalysts in the synthesis of single enantiomer compounds is of increasing interest, but requires novel substrate specific highly stereoselective biocatalysts. Addition to the limited toolbox of known nitrile biocatalysts requires definitive characterisation of the biocatalysts through accurate determination of the substrate profiles and quantification of activity. The accurate quantification of stereoisomers chiral mixtures to determine biocatalyst stereoselectivity remains a significant challenge due to the difficulty in separating stereoisomers by physical methods. The known nitrile metabolising organism, Rhodococcus rhodochrous ATCC BAA-870, was grown in a defined medium and harvested, providing whole cell biocatalyst. Additional biomass was disrupted to provide a cell free enzyme extract, which was put through an enzyme purification protocol to provide a solution with specific activity of 351 U.mg⁻¹. A portion of the enzyme was self immobilised using the SphereZyme™ technique. The nitrile hydratase SphereZymes™ (1.2 U.mg⁻¹ initial activity) that were prepared had pH and temperature optima of 6 and 30°C respectively, and could be recovered by repeated washing. The particles retained activity in the presence of the organic solvents isooctane and n-hexadecane saturated with 50 mM phosphate buffer (pH 7.5). An initial analytical system was devised for quantification of the nitrile hydratase activity using the non-chiral substrate benzonitrile. An improved reversed phase high performance liquid chromatography method was developed to separate and quantify benzamide, benzoic acid and benzonitrile. The mobile phase consisting of 0.1% trifluoroacetic acid in H₂O and acetonitrile (70:30, %v/v), at a flow rate of 0.5 ml.ml⁻¹, 25°C, resolved all three analytes in 3.5 minutes on a Waters X-Terra MS C18 3.5μm column. UV detection was carried out at 210 nm. Analytical methods to determine activity and enantioselectivity of the whole cell biocatalyst were subsequently developed for both β-amino nitriles and β-hydroxy nitrile substrates and hydrolysis products.

Human chorionic gonadotropin (HCG), a glycoprotein hormone with two nonidentical subunits, is produced by chorionic tissue in pregnant women and by neoplastic tissue containing chorionic elements. It is used in the treatment of male hypogonadism and female sub-fertility. Quantitation of HCG is used to monitor therapy, diagnose various disease states and diagnose and monitor pregnancy. Low levels of HCG in the early and late stages of pregnancy and in various disease states has prompted the development of extremely sensitive assay procedures. Clinically, radioimmunoassay methods are most frequently used due to their precision, sensitivity and cost. However, problems with specificity have been noted. Commercial preparations of HCG must meet the standards outlined in the United States Pharmacopeia (USP). The assay procedure involves a rat uterine weight bioassay. This protocol is lengthy to perform (5 days), requires the sacrifice of a large number of animals (minimum of 60 female rats per assay) and may need to be repeated if the results do not meet the statistical requirements of the assay. Due to the use of animals and the animal care facilities required, this is an expensive assay. In addition, the bioassay is not specific for HCG. Therefore, this thesis reports the analysis of two commercial preparations of HCG, as well as USP Reference Standard HCG and commercially available purified intact HCG and purified individual subunits. Various HPLC assay procedures were evaluated to determine if HPLC would be a viable alternative to the official USP bioassay. Size exclusion HPLC, using one Protein Pak 125 sw column and two Protein Pak 300 sw columns individually and in various combinations, was used to assess all the samples of HCG. Attempts to increase resolution of HCG from interfering components found in these preparations included using both 208 nm and 278 nm for ultraviolet detection, evaluation of 32 buffers as mobile phases with the Protein Pak 300 sw column, fluorescamine derivatization of HCG followed by fluorescence detection, connection of two size exclusion columns in series, and recycling on a Protein Pak 300 sw column. Further attempts to isolate HCG from its protein contaminants involved using ion exchange HPLC with a Protein Pak DEAE 5 pw column with 20 different buffers as mobile phases as well as reversed-phase HPLC with an Ultrasphere ODS column. The greatest resolution was obtained with one Protein Pak 300 sw column with a phosphate buffer (0.15 M, pH 7.0) for the mobile phase and ultraviolet detection. Latex agglutination inhibition slide tests and electrophoresis techniques were used to evaluate commercial samples of HCG and chromatographic peak eluates. Commercial HCG samples appear to contain the individual subunits of HCG and intact HCG along with impurities. The USP Reference Standard HCG contains intact HCG but also contains other ultraviolet absorbing components that were partially separated by HPLC. Electrophoresis also indicated that this HCG sample contained impurities. In addition, the purified intact HCG and purified subunit samples contained impurities, as shown by HPLC. The size exclusion HPLC assay developed using one Protein Pak 300 sw column was unable to resolve intact HCG from the beta-subunit. This assay would be useful for a qualitative assay for purity of HCG preparations. However, at present, HPLC is not a viable alternative to the USP bioassay. / Pharmaceutical Sciences, Faculty of / Graduate

An objective analytical method was developed to characterize the taste profiles of five cheese varieties. Nonvolatile water extracts of Cheddar, Edam, Gouda, Swiss, and Parmesan cheeses were analyzed by high performance liquid chromatography (HPLC) with a reversed phase column. The HPLC operating conditions were determined with Mapping Super-Simplex followed by Centroid Mapping Optimization. A ternary gradient elution system was used with an Adsorbosphere C8 column to resolve a maximum number of components. The optimum solvent volume ratio was 96.8 : 1.2 : 2.0 for trifluoroacetic acid (0.1%), acetonitrile, and methanol, with a flow rate of 1.0 mL/min. Over 50.3 min this ratio was changed to 56.3 : 30.3 : 13.4. Multivariate statistical analyses including principal component and discriminant analyses were applied to 55 peak areas from 106 cheese chromatograms. Principal component analysis reduced the dimensionality of the "data from 55 to 17 principal components, which are-combinations of the original variables, with a 26% loss of explained sample variation. Discriminant analysis on data from a single HPLC column was able to correctly classify cheeses by variety at a greater than 90% success rate. This grouping rate dropped to 64% when data from all four HPLC columns was combined, implicating large between column variations. A semi-trained sensory panel correctly classified cheeses by variety at a 63% rate. This objective method provides a lasting fingerprint of cheese products. / Land and Food Systems, Faculty of / Graduate

Tissues are heterogeneous ecosystems comprised of various cell types. For example, in tumor tissues, malignant cancer cells are surround by various non-malignant stromal cells. Proteins, especially N-linked glycoproteins, are key players in tumor microenvironment and respond to many extracellular stimuli for involving and regulating intercellular signaling. Understanding the human proteome and glycoproteome in heterogeneous tissues with spatial resolution are meaningful for exploring intercellular signaling networks and discovering protein biomarkers for various diseases, such as cancer. In this study, we aimed to develop new liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based analytical methods for spatially-resolved proteome and glycoproteome profiling in tissue samples, and apply them for profiling potential biomarkers for pancreatic cancer. We first systematically and synchronously optimized the LC-MS parameters to increase peptide sequencing efficiency in data dependent proteomics. Taking advantage of its hybrid instrument design with various mass analyzer and fragmentation strageties, the Orbitrap Fusion mass spectrometer was used for systematically comparing the popular high-high approach by using orbitrap for both MS1 and MS2 scans and high-low approach by using orbitrap for MS1 scan and ion trap for MS2 scans. High-high approach outperformed high-low approach in terms of better saturation of the scan cycle and higher MS2 identification rate. We then systematically optimized various MS parameters for high-high approach. We investigated the influence of isolation window and injection time on scan speed and MS2 identification rate. We then explored how to properly set dynamic exclusion time according to the chromatography peak width. Furthermore, we found that the orbitrap analyzer, rather than the analytical column, was easily saturated with higher peptide loading amount, thus limited the dynamic range of MS1-based quantification. Finally, by using the optimized LC-MS parameters, more than 9000 proteins and 110,000 unique peptides were identified by using 10 hours of effective LC gradient time. The study therefore illustrated the importance of synchronizing LC-MS precursor targeting and high-resolution fragment detection for high-efficient data dependent proteomics. Understanding the tumor heterogeneity through spatially resolved proteome profiling is meaningful for biomedical research. Laser capture microdissection (LCM) is a powerful technology for exploring local cell populations without losing spatial information. Here, we designed an immunohistochemistry (IHC)-based workflow for cell type-resolved proteome analysis of tissue samples. Firstly, targeted cell type was stained by IHC using antibody targeting cell-type specific marker to improve accuracy and efficiency of LCM. Secondly, to increase protein recovery from chemically crosslinked IHC tissues, we optimized a decrosslinking procedure to seamlessly combine with the integrated spintip-based sample preparation technology SISPROT. This newly developed approach, termed IHC-SISPROT, has comparable performance with traditional H&E staining-based proteomic analysis. High sensitivity and reproducibility of IHC-SISPROT was achieved by combining with data independent proteomic analysis. This IHC-SISPROT workflow was successfully applied for identifying 6660 and 6052 protein groups from cancer cells and cancer- associated fibroblasts (CAFs) by using only 5 mm 2 and 12 μm thickness of hepatocellular carcinoma tissue section. Bioinformatic analysis revealed the enrichment of cell type-specific ligands and receptors and potentially new communications between cancer cells and CAFs by these signaling proteins. Therefore, IHC-SISPROT is sensitive and accurate proteomic approach for spatial profiling of cell type-specific proteome from tissues. N-linked glycoproteins are promising candidates for diagnostic and prognostic biomarkers and therapeutic targets. They often locate at plasma membrane and extracellular space with distinct cell type distribution in tissue microenvironment. Due to access to only low microgram of proteins and low abundance of glycoproteins in tissue sections harvested by LCM, region- and cell type-resolved glycoproteome analysis of tissue sections remains challenging. Here we designed a fully integrated spintip-based glycoproteomic approach (FISGlyco) which achieved all the steps for glycoprotein enrichment, digestion, deglycosylation and desalting in a single spintip device. Sample loss is significantly reduced and the total processing time is reduced to 4 hours, while detection sensitivity and label-free quantification precision is greatly improved. 607 N-glycosylation sites were successfully identified and quantified from only 5 μg of mouse brain proteins. By seamlessly combining with LCM, the first region-resolved N-glycoproteome profiling of four mouse brain regions, including isocortex, hippocampus, thalamus, and hypothalamus, was achieved, with 1,875, 1,794, 1,801, and 1,417 N-glycosites identified, respectively. Our approach could be a generic approach for region and even cell type specific glycoproteome analysis of tissue sections. Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with five year survival rate of around 8%. No effective biomarkers and targeted therapy are one of the major reasons for this urgent clinical situation. To explore potential protein biomarkers and drug targets located at intercellular space of pancreatic tumor microenvironment, we established chemical proteomic approach for deep glycoproteome profiling of PDAC clinical tissue samples based on the above- mentioned new proteomic methods. Taking advantage of a long chain biotin- hydrazide probe with less space hindrance, the new method outperformed traditional hydrazide chemistry method in terms of sensitivity, time efficiency and glycoproteome coverage. The method was successfully applied to enrich and validate LIF and its receptors as potential biomarkers for PDAC. In addition, to explore the full map of pancreatic tumor microenvironment glycoproteome with diagnostic and therapeutic values, we collected 114 pancreatic tissues, including 30 PDAC tumor tissues, 30 adjacent non-tumor (NT) tissues, 32 chronic pancreatitis tissues and 22 normal pancreatic tissues, and systematically profiled their glycoprotein expression pattern by using the developed glycoproteomic strategy. The deepest glycoproteome of PDAC was achieved, which covered the majority of previously reported glycoprotein biomarkers and drug targets for PDAC. Importantly, we discovered many new glycoproteins with differential expression in PDAC and normal tissue types. Moreover, LCM-based cell-type proteome profiling was achieved for 13 PDAC tissue samples, which covered more than 8000 proteins for both pancreatic stromal cells and pancreatic cancer cells in each sample. We therefore provided a valuable resource for screening novel and cancer specific glycoprotein biomarkers for pancreatic cancer with spatial resolution

Antibodies to tropomyosin, cardiac troponin I, myosin, and the beta-adrenergic receptors have been implicated in myocarditis, dilated cardiomyopathy, and heart failure. However, in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), there are only a few studies on how autoantibodies play a role in autoimmune mediated heart disease, despite the prevalence of these conditions. Ro52 antibodies have been implicated in fetal heart block, but their role in adult myocarditis remains elusive. In this study, we look beyond Ro52 and characterized the relevant autoantibodies in adult patients with SLE and RA myocarditis. An optimized immunoprecipitation followed by liquid chromatography mass spectrometry methodology was performed to determine putative auto-antigens in the human heart. The quantity and specificity of auto-antibodies was correlated with clinical measures of myocardial cellular infiltration, as determined by fluorodeoxyglucose (FDG)-positron emission tomography (PET) in patients with SLE and RA. We created autoantibody profiles that are complimentary to SLE and RA patients' clinical profile. Autoantibodies that correlated with cellular infiltration included TPI1, TPM1, MYL2, XRCC6 and APOA4. We then explored methodologies for testing patient autoantibodies using engineered cardiac tissues derived from human induced pluripotent stem cells (iPSCs). These tissues are increasingly used for drug discovery, pharmacology and in models of development and disease. While there are numerous platforms with engineered cardiac tissues, they often require expensive and non-conventional equipment and utilize complex video processing algorithms. As a result, only specialized academic labs have been able to harness this technology. In addition, methodologies and tissue features have been challenging to reproduce between different groups and models. Here, we describe a facile technology (milliPillar) that covers the entire pipeline required for studies of engineered cardiac tissues: (i) platform fabrication, (ii) cardiac tissue generation, (iii) electrical stimulation, (iv) automated real-time data acquisition, and (v) advanced video analyses. We validate these methodologies and demonstrate the versatility of the platform by showcasing the fabrication of tissues in different hydrogel materials and by using cardiomyocytes derived from different iPSC lines in combination with different types of stromal cells. We also validate the long-term culture (100 days) of tissues within the platform and provide protocols for automated analysis of force generation and calcium flux using both brightfield and fluorescent imaging. Lastly, we demonstrate the compatibility of the milliPillar platform with electromechanical stimulation to enhance cardiac tissue function. milliPillar tissues were cultured in the presence of patient autoantibodies to recapitulate the phenotype of myocardial disease, and the calcium transients and force generation were measured. Our results indicated that milliPillar tissues exhibited a decrease in force generation after 6 days in culture with SLE autoantibodies. Separately, our results indicated a prolonged calcium transient after 7 days in culture with SLE and RA autoantibodies. Changes to the downstroke of the calcium transient correlated most with patients’ autoantibody profiles and cellular infiltration. We confirmed autoantibody binding to live tissues/cells in 25% of the patients with SLE and myocarditis. Finally, we used changes in cardiac tissue function in the presence of autoantibodies to classify patients with SLE myocarditis with an accuracy of 87.5%.

The aim of this diploma thesis was to develop and validate a high performance liquid chromatography (HPLC) method for purity and stability evaluation of fesoterodine. The HPLC method development was carried out using design of experiments (DOE), which allows to find optimal separation conditions within small number of experimental analysis. Design was done by using L18 linear model. Chromatographic system of the developed method consisted of a C8 stationary phase (SF) XBridge BEH - C8 (100 x 4.6 mm, 2.5 µm), a binary mobile phase (MF) consisting of 10mM borate buffer pH 9.2 and MeOH in various ratios according to the gradient program. Flow rate was 0.7 ml/min, column temperature 35 řC and a diode-array detector (DAD) was applied for the detection at 227 nm. Analysis time was 22 min. The optimized method was validated and the forced degradation study was performed. Studied effects were: the effect of elevated temperature (60 řC), humidity (10 and 75% relative humidity), acidic and basic conditions, oxidation and light. Peak purity of fesoterodine was evaluated for all experiments of forced degradation study. Additionally, the sensitivity of the active substance to hydrolysis was determined within the pH range of 2-10.

Protamine, a set of small basic proteins (P1 and P2), play a key role in compacting and protecting the DNA in sperm. As such, the structure of how P1 and P2 bind to DNA and potentially themselves and each other is of interest to several fields including forensics. In forensic DNA analysis, protamine binding of DNA is taken advantage of in the “differential extraction” procedure in which a sample that contains sperm and non-sperm cells can have DNA from the two different cell types separated and extracted at different points thus preventing a mixture of DNA. A key component of this greater structure and what makes the differential extraction functional are the disulfide bonds formed by protamine. So as a first step to elucidating the protamine-DNA complex, methods to analyze human protamine via 2D-Liquid Chromatography-Mass Spectrometry (2D-LC-MS) were developed in the hopes they could be used for disulfide bond mapping. Methods and multiple strategies for digestion, 2D-LC-MS were investigated and developed using chum salmon protamine. Digestion strategies were developed for Chymotrypsin and Lys-C, Trypsin or Arg-C with incubation times and substrate:enzyme mass ratios optimized. Various “trap and elute” 2D-chromatography configuration were tested for analysis intact and digested protein. Using H2O with 2% NH4OH as the loading mobile phase and H2O and Acetonitrile both with 0.5% formic acid as the eluting mobile phases with the first dimension column being an HLB (Hydrophilic Lipophilic Balance) 2.1 x 30 mm column and the second dimension being an C18 2.1 x 100 mm was found to produce the highest signal.

Introduction. Popularity of electronic cigarettes (e-cigarettes) has increased dramatically in recent years, especially among adolescents. The most recent data from the National Institute on Drug Abuse (NIDA) cites that >16% of 12th graders have tried e-cigarettes, and >30% of those individuals will start smoking within 6 months1. E-cigarettes are available in a variety of ‘strengths’ indicating the labeled nicotine concentration in the product. In this project, we sought to investigate the accuracy of nicotine labeling found in some commercially available e-liquids. As such, we developed and validated a liquid chromatography-mass spectrometry (LC-MS) assay to determine the nicotine concentration in these products. Methods. A literature search revealed that the two most commonly used chromatographic approaches for nicotine are hydrophilic interaction liquid chromatography (HILIC) and reversed phase chromatography (RP). Both options were evaluated, and nicotine peak quality and reproducibility were assessed. Mass spectrometric conditions for positive electrospray (+ESI) ionization were optimized, including collision energy and ion accumulation time. The optimized method included a gradient separation using a UCT C18 column (2.1 x 100 mm; 1.8 micron) with acetonitrile as the organic phase and 0.1% formic acid in water as the aqueous phase. Nicotine stock solutions were prepared in 100% ethanol and diluted in acetonitrile to achieve calibration concentrations (5 – 75 micrograms/mL). Deuterium labeled nicotine (d4) was used as the internal standard at a concentration of 10 micrograms/mL. The method was evaluated for precision, reflected by percent relative standard deviation (%RSD) and accuracy, or percent error, at each concentration for three days. The method was applied to the assessment of nicotine concentration in samples of e-liquids labeled as 3 mg/mL nicotine. Results. Reversed phase chromatography outperformed HILIC separation for nicotine under the conditions tested. The final RP-LC-MS/MS method involves direct monitoring of m/z 163.1219 for quantification of nicotine (167.1219 for d4-nicotine). The method exhibits < 15% RSD and < 15% error for all concentrations in the calibration range (< 20% at the lower limit of quantification). The developed method allows for rapid throughput, with a run time of 5 minutes. The lower limit of detection was determined to be 1 microgram/mL. Of the e-liquids evaluated, variations of up to 37% from the labeled amount of 3 mg/mL were detected. Additionally, a product labeled ‘zero nicotine’ contained no detectable nicotine. Conclusions. A fast, accurate, and reproducible LC-MS/MS assay has been developed and validated for the determination of nicotine in e-cigarette liquids. This method was applied to the evaluation of e-liquids, which showed significant variability in nicotine content from the labeled amount. 1 https://www.drugabuse.gov/related-topics/trends-statistics/infographics/teens-e-cigarettes

Background: Moxifloxacin is a new fourth-generation 8-methoxy fluoroquinolone developed primarily for the treatment of community-acquired pneumonia and upper respiratory tract infections. The aim of the study was to investigate the plasma pharmacokinetics characteristic of moxifloxacin in calves, after intravenous, intramuscular and subcutaneous administration of a single dose. Meanwhile, plasma protein binding and bioavailability of moxifloxacin were also estimated. Methods: Plasma concentrations of moxifloxacin were measured using a modified HPLC method, and the extent of plasma protein binding was determined in vitro using ultrafiltration. Results: Following intravenous administration, the half life of elimination, the volume of distribution at steady state and the area under the curve were 3.29 h, 0.94 l/kg and 24.72 μg·h/ml, respectively. After intramuscular and subcutaneous administration of moxifloxacin at the same dose, the peak plasma concentrations were 2.41 and 2.20 μg/ml and were obtained at 1.54 and 1.59 h, respectively. The systemic bioavailabilities were 87.19 and 75.94%, respectively. The in vitro plasma protein binding of moxifloxacin in plasma of calves was 27%. Conclusion: A high peak plasma concentration, area under the curve, rapid absorption and bioavailability following intramuscular and subcutaneous administration characterize the pharmacokinetics of moxifloxacin in calves.